Essec\Faculty\Model\Contribution {#2233
  #_index: "academ_contributions"
  #_id: "14782"
  #_source: array:26 [
    "id" => "14782"
    "slug" => "les-cellules-car-t-prix-efficience-et-soutenabilite-en-france"
    "yearMonth" => "2024-04"
    "year" => "2024"
    "title" => "Les cellules CAR-T : prix, efficience et soutenabilité en France"
    "description" => "PUYOU DE POUVOURVILLE, G. (2024). Les cellules CAR-T : prix, efficience et soutenabilité en France. <i>Bulletin de l'Académie Nationale de Médecine</i>, In press."
    "authors" => array:1 [
      0 => array:3 [
        "name" => "PUYOU DE POUVOURVILLE Gérard"
        "bid" => "B00072308"
        "slug" => "de-pouvourville-gerard"
      ]
    ]
    "ouvrage" => ""
    "keywords" => array:4 [
      0 => "Car-T cells"
      1 => "price"
      2 => "cost-efficency"
      3 => "sustainability"
    ]
    "updatedAt" => "2024-04-24 11:07:17"
    "publicationUrl" => "https://doi.org/10.1016/j.banm.2024.01.020"
    "publicationInfo" => array:3 [
      "pages" => ""
      "volume" => "In press"
      "number" => ""
    ]
    "type" => array:2 [
      "fr" => "Articles"
      "en" => "Journal articles"
    ]
    "support_type" => array:2 [
      "fr" => "Revue scientifique"
      "en" => "Scientific journal"
    ]
    "countries" => array:2 [
      "fr" => null
      "en" => null
    ]
    "abstract" => array:2 [
      "fr" => "La soutenabilité des dépenses pour les cellules CAR-T dans le futur est fonction de l’efficacité des mécanismes de fixation des prix en France, remises et contrats à la performance fondée sur des données en vie réelle. Les coûts de production vont baisser, mais l’émergence d’acteurs privés à but non lucratif aurait un impact majeur sur les prix. Les pertes de brevet attendues de médicaments à fort impact budgétaire vont dégager des marges de manœuvre pour le payeur public en France."
      "en" => "The sustainability of spending on CAR-T cells in the future depends on the effectiveness of pricing mechanisms in France, discounts and performance-based contracts based on real-life data. Production costs will fall, but the emergence of private, non-profit players would have a major impact on prices. The expected patent losses for drugs with a strong budgetary impact will generate major savings for the French public payer."
    ]
    "authors_fields" => array:2 [
      "fr" => "Management"
      "en" => "Management"
    ]
    "indexedAt" => "2024-11-23T15:21:42.000Z"
    "docTitle" => "Les cellules CAR-T : prix, efficience et soutenabilité en France"
    "docSurtitle" => "Articles"
    "authorNames" => "<a href="/cv/de-pouvourville-gerard">PUYOU DE POUVOURVILLE Gérard</a>"
    "docDescription" => "<span class="document-property-authors">PUYOU DE POUVOURVILLE Gérard</span><br><span class="document-property-authors_fields">Management</span> | <span class="document-property-year">2024</span>"
    "keywordList" => "<a href="#">Car-T cells</a>, <a href="#">price</a>, <a href="#">cost-efficency</a>, <a href="#">sustainability</a>"
    "docPreview" => "<b>Les cellules CAR-T : prix, efficience et soutenabilité en France</b><br><span>2024-04 | Articles </span>"
    "docType" => "research"
    "publicationLink" => "<a href="https://doi.org/10.1016/j.banm.2024.01.020" target="_blank">Les cellules CAR-T : prix, efficience et soutenabilité en France</a>"
  ]
  +lang: "fr"
  +"_type": "_doc"
  +"_score": 8.670292
  +"parent": null
}